Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 30 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell CarcinomaActive, not recruitingNCT04393350Phase 2Results posted
• Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)CompletedNCT04385368Phase 3Results posted
• Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder CancerCompletedNCT04383743Phase 2Results posted
• PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)TerminatedNCT04382898Phase 1/2Results posted
• Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerTerminatedNCT04373369Phase 2Results posted
• Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerActive, not recruitingNCT04373031Phase 2Results posted
• ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-ImmunotherapyTerminatedNCT04372927Phase 2Results posted
• Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced MalignanciesCompletedNCT04370704Phase 1/2Results posted
• Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing SurgeryTerminatedNCT04370509Phase 2Results posted
• Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung CancerTerminatedNCT04364048Phase 2Results posted
• A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal CancerTerminatedNCT04363801Phase 2Results posted
• Study of AMG 256 in Adult Subjects With Advanced Solid TumorsCompletedNCT04362748Phase 1Results posted
• Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung CancerTerminatedNCT04348292Phase 1Results posted
• A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver CancerCompletedNCT04340193Phase 3Results posted
• Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue SarcomaActive, not recruitingNCT04339738Phase 2Results posted
• Cemiplimab in AlloSCT/SOT Recipients With CSCCCompletedNCT04339062Phase 1/2Results posted
• A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor TreatmentTerminatedNCT04338269Phase 3Results posted
• Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen LoadTerminatedNCT04336943Phase 2Results posted
• DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural MesotheliomaCompletedNCT04334759Phase 3Results posted
• NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT04332653Phase 1/2Results posted
• Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast CancerTerminatedNCT04331067Phase 1/2Results posted
• Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior ImmunotherapyCompletedNCT04326257Phase 2Results posted
• Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping MutationsTerminatedNCT04323436Phase 2Results posted
• Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial CarcinomaTerminatedNCT04322643Phase 2Results posted
• Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT04318080Phase 2Results posted
• Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTENActive, not recruitingNCT04317105Phase 1/2Results posted
• A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)CompletedNCT04317066Phase 1Results posted
• Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCCCompletedNCT04313504Phase 2Results posted
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaTerminatedNCT04310397Phase 2Results posted
• TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced CancersCompletedNCT04306900Phase 1Results posted
• Study of Pembrolizumab and Olaparib in Bile Duct CancerCompletedNCT04306367Phase 2Results posted
• Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)CompletedNCT04303169Phase 1/2Results posted
• A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical CancerCompletedNCT04300647Phase 2Results posted
• BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04284787Phase 2Results posted
• Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)CompletedNCT04282109Phase 2Results posted
• Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid LeukemiaCompletedNCT04277442Phase 1Results posted
• Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without TislelizumabCompletedNCT04276493Phase 1/2Results posted
• Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial CancerActive, not recruitingNCT04269200Phase 3Results posted
• Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDYTerminatedNCT04268277Phase 2Results posted
• Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)TerminatedNCT04267120Phase 2Results posted
• Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid TumorsActive, not recruitingNCT04266912Phase 1/2Results posted
• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)TerminatedNCT04266301Phase 3Results posted
• Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate CancerActive, not recruitingNCT04262154Phase 2Results posted
• CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate AccumulationsCompletedNCT04260529Phase 1/2Results posted
• A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04256421Phase 3Results posted
• Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor ProgressionTerminatedNCT04251169Phase 2Results posted
• Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for ChemotherapyCompletedNCT04249362Phase 2Results posted
• Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Phase 3Results posted
• Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast CancerActive, not recruitingNCT04243616Phase 2Results posted
• Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCCTerminatedNCT04242173Phase 2Results posted
• Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)CompletedNCT04231981Phase 2Results posted
• Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial CancerActive, not recruitingNCT04223856Phase 3Results posted
• Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)CompletedNCT04221945Phase 3Results posted
• A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 StudyActive, not recruitingNCT04215146Phase 2Results posted
• Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced MalignanciesTerminatedNCT04214418Phase 1/2Results posted
• Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung CancerActive, not recruitingNCT04214262Phase 3Results posted
• BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04214249Phase 2Results posted
• MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer PatientsTerminatedNCT04212221Phase 1/2Results posted
• Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric AdenocarcinomaCompletedNCT04209686Phase 2Results posted
• A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder CancerCompletedNCT04209114Phase 3Results posted
• Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerCompletedNCT04205812Phase 3Results posted
• Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesCompletedNCT04205409Phase 2Results posted
• Cabozantinib and Nivolumab for Carcinoid TumorsCompletedNCT04197310Phase 2Results posted
• A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Phase 3Results posted
• A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck CancerTerminatedNCT04193293Phase 1/2Results posted
• Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic CancerCompletedNCT04191421Phase 1/2Results posted
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)TerminatedNCT04191096Phase 3Results posted
• Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast CancerTerminatedNCT04190056Phase 2Results posted
• Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness GenesCompletedNCT04187833Phase 2Results posted
• A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/ParagangliomaTerminatedNCT04187404Phase 1/2Results posted
• Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced MalignanciesCompletedNCT04181788Phase 1/2Results posted
• Plerixafor and Cemiplimab in Metastatic Pancreatic CancerCompletedNCT04177810Phase 2Results posted
• A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerCompletedNCT04177108Phase 3Results posted
• Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)CompletedNCT04173507Phase 2Results posted
• Talabostat and Pembrolizumab for the Treatment of Advanced Solid CancersTerminatedNCT04171219Phase 2Results posted
• Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural MesotheliomaTerminatedNCT04166734Phase 1Results posted
• VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)TerminatedNCT04166383Phase 2Results posted
• A Study of Sasanlimab in People With Non-muscle Invasive Bladder CancerActive, not recruitingNCT04165317Phase 3Results posted
• Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal AdenocarcinomaCompletedNCT04164979Phase 2Results posted
• Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLCTerminatedNCT04163432Phase 2Results posted
• ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerTerminatedNCT04159896Phase 2Results posted
• Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell CarcinomaCompletedNCT04154943Phase 2Results posted
• A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)CompletedNCT04153565Phase 1Results posted
• Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)TerminatedNCT04152863Phase 2Results posted
• 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and NeckActive, not recruitingNCT04150900Phase 2Results posted
• A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for ChemotherapyTerminatedNCT04150029Phase 2Results posted
• A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)TerminatedNCT04149574Phase 3Results posted
• A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast CancerCompletedNCT04148911Phase 3Results posted
• A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)CompletedNCT04147234Phase 1Results posted
• A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck CancerCompletedNCT04144517Phase 2Results posted
• Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in MelanomaActive, not recruitingNCT04139902Phase 2Results posted
• Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)CompletedNCT04126733Phase 2Results posted
• Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed TumorsActive, not recruitingNCT04126070Phase 2Results posted
• A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant MelanomaCompletedNCT04123470Phase 1/2Results posted
• Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung CancerCompletedNCT04120454Phase 2Results posted
• Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory MyelomaTerminatedNCT04119336Phase 2Results posted
• Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue SarcomaCompletedNCT04118166Phase 2Results posted
• INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary CancerCompletedNCT04116073Phase 2Results posted
• Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast CancerCompletedNCT04109066Phase 3Results posted
• A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Phase 3Results posted

← Immune Checkpoint Inhibitors overview